Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy

To study infliximab (IFX) pharmacokinetics in children with inflammatory bowel disease (IBD) during induction therapy to predict outcome and explore if other covariates influenced outcome. All children with IBD starting IFX therapy (5 mg/kg at weeks 0, 2, 6, and 12) for active luminal disease from M...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of pediatrics 2022-01, Vol.240, p.150-157.e4
Main Authors:	van Hoeve, Karen, Seyed Tabib, Nasim Sadat, Dreesen, Erwin, Tops, Sophie, Hoffman, Ilse, Gils, Ann, Ferrante, Marc, Vermeire, Séverine
Format:	Article
Language:	eng
Subjects:	Adolescent Child Child, Preschool children Drug Monitoring Endoscopy, Digestive System Female Follow-Up Studies Gastrointestinal Agents - blood Gastrointestinal Agents - therapeutic use Humans inflammatory bowel disease Inflammatory Bowel Diseases - drug therapy infliximab Infliximab - blood Infliximab - therapeutic use Male outcome Prospective Studies proteomics Remission Induction therapeutic drug monitoring
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To study infliximab (IFX) pharmacokinetics in children with inflammatory bowel disease (IBD) during induction therapy to predict outcome and explore if other covariates influenced outcome. All children with IBD starting IFX therapy (5 mg/kg at weeks 0, 2, 6, and 12) for active luminal disease from May 2017 to May 2019 were included and followed prospectively. Patients were sampled at multiple timepoints during induction (trough concentrations and peak concentration at weeks 0, 2, 6, and 12, and intermediate concentration at weeks 1-4). IFX concentrations and cumulative drug exposure were correlated with outcome at 6 months. Endoscopic remission was defined as Simple Endoscopic Score for Crohn's Disease of
ISSN:	0022-3476 1097-6833